Posted by Michael Wonder on 16 Jun 2021
Medicare must study unproven, expensive Alzheimer’s drug
15 June 2021 - Tax payers and patients cannot afford to pay a high price for a treatment not known to be effective.
The cost of caring for America’s nearly 6 million Alzheimer’s disease patients is already $600 billion a year, factoring in the cost of uncompensated caregiving.
Now, the FDA has approved a drug treatment that may or may not work but is set to cost $56,000 a year for the average patient — a charge that in most instances will fall to Medicare.
